感染

订阅

MedSci主页 / 所有栏目 / 感染

Nat Biotechnology：科学家成功激活无效HIV抗体

2014-01-02 张笑 编译 中国科学报

HIV抗药性抗体ibalizumab
关注

《自然—生物技术》上的一项报告介绍了一种可重新激活已被HIV产生抗药性的治疗抗体的方法。除了介绍改造抗体以使其重新对大批HIV-1病毒株有效的改进方法外，报告作者还认为这种改进方法对其他治疗抗体也会有用。 此次研究涉及到的抗体名为ibalizumab，通过阻断HIV-1为进入细胞而使用的一种受体的方式发挥作用。但是，某些病人体内的HIV-1病毒株在受到ibalizumab作用时，会发生一


《自然—生物技术》上的一项报告介绍了一种可重新激活已被HIV产生抗药性的治疗抗体的方法。除了介绍改造抗体以使其重新对大批HIV-1病毒株有效的改进方法外，报告作者还认为这种改进方法对其他治疗抗体也会有用。

此次研究涉及到的抗体名为ibalizumab，通过阻断HIV-1为进入细胞而使用的一种受体的方式发挥作用。但是，某些病人体内的HIV-1病毒株在受到ibalizumab作用时，会发生一些特殊突变从而对抗体产生抵抗性。结构性研究显示，这些突变会通过在病毒与抗体之间引入空隙的方式来弱化HIV-1和ibalizumab之间的相互作用。


因为怀疑这种空隙有利于HIV-1产生抗药性，David Ho等人推断将其“重新填充”可能会阻止病毒的侵入动作。为了验证假设，他们在ibalizumab与病毒产生反应的位置附近标记上一种碳水化合物。结果，标记后的抗体100%中和了试验用到的HIV-1病毒株，其中包括那些之前已对原始抗体产生了抗药性的病毒。

原文出处：

Ruijiang Song, Deena A Oren, David Franco, Michael S Seaman& David D Ho. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1 –neutralizing activity. Nature Biotechnology, 06 October 2013; doi:10.1038/nbt.2677【原文下载】

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
    2014-11-16 sunylz

    #Bio#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
    2014-04-23 Homburg

    #HIV抗体#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
    2014-12-18 shock_melon

    #TEC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
    2014-02-05 fzwish20000

    #Technology#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
    2014-06-18 cathymary

    #Biotech#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1917011, encodeId=66db191e01156, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Nov 16 22:48:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036523, encodeId=d2c6203652340, content=<a href='/topic/show?id=8ebe8910d5' target=_blank style='color:#2F92EE;'>#HIV抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8910, encryptionId=8ebe8910d5, topicName=HIV抗体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Apr 23 03:48:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652090, encodeId=0f161652090d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Dec 18 16:48:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795570, encodeId=52cd1e955706b, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Feb 05 10:48:00 CST 2014, time=2014-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927605, encodeId=7405192e60570, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jun 18 01:48:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879829, encodeId=b8cf18e9829d5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 11 08:48:00 CST 2014, time=2014-11-11, status=1, ipAttribution=)]
    2014-11-11 liye789132251

    #Nat#

    0

相关资讯

Science ：科学家发现一种能击垮RSV的新型抗体

　　通过进攻病毒F蛋白质表面的脆弱部位，一种新型抗体能击垮RSV 图片来源： JONATHAN STUCKEY 在艾滋病病毒（HIV）实验室，一名资深科学家领导的团队正在研制一种急需的能够抵御呼吸道合胞体病毒（RSV，是婴儿的主要杀手）的疫苗，他们的研究已经取得了令人惊叹的硕果。 作为同类疫苗中的首个尝试，博士后Barney Gr

Nature：美揭示疫苗抵抗SIV/HIV感染的机制

猴免疫缺陷病毒（simian immunodeficiency virus, SIV）是一种非常类似于人免疫缺陷病毒（human immunodeficiency virus, HIV）的病毒。它主要利用病毒刺突（sipke）感染细胞。 日前，来自美国家过敏症和传染病研究所（NIAID）等机构的科学家们在猴子体内开展了一

Nat Immunol：艾滋病患者抗体反应为何较弱？

为什么HIV病人抗体反应比较弱?现在一项刊登在《自然—免疫学》上论文给出的答案：位于HIV 病毒表面的糖蛋白gp120可让人体B免疫细胞失去活性。 人们已经发现 HIV 能够引起 CD4+ 辅助性T免疫细胞不断丧失，导致免疫系统功能受损、其他感染更容易乘机而入。但人们一直没有弄清为何在 HIV 感染早期，T细胞数量还处于相对正常时，人体就不产生有力的抗体反应了。 在这项研究中，来自美国

Nature：研究揭示HIV导致CD4 T细胞死亡的分子机制

HIV导致艾滋病，主要是因为病毒破坏了重要的免疫细胞：CD4 T细胞，然而一直以来都并不清楚确切杀死这些细胞的机制。同时发表在12月19日《自然》（Nature）和《科学》（Science）杂志上的两篇新论文揭示了，感染过程中导致淋巴组织中大多数CD4 T细胞死亡的分子机制。 由Gladstone研究所著名教授Warner Greene领导的两个研究小组证实

西班牙将对艾滋病感染者进行治疗性疫苗试验

图片来源：巴基斯坦新闻网 据“中央社”报道，西班牙一所医院的研究人员9日宣布，他们明年将针对已感染艾滋病毒(HIV)的病患，进行一种治疗性疫苗试验。 报道称，这一治疗性疫苗是用以治疗疾病，而非加以预防。巴塞隆纳这所医院表示，院内将进行这项试验，以配合该院与西班牙、比利时及荷兰其他医院共同进的这项4年研究计划。 该院传染病科主任贾德尔(Josep Maria&

JAMA ：微量营养补充剂可降低艾滋病患病风险

芝加哥 – 据11月27日发表在《美国医学会杂志》上的一则研究披露，长期(24个月)给位于博茨瓦纳的感染了人类免疫缺陷性病毒(HIV)但处于疾病早期且没有接受抗逆转录病毒治疗的患者补充多种维生素加硒可延迟HIV疾病进展的时间，这种方法是安全的，而且能减少免疫功能下降及患病的风险。 根据文章的背景资料：“即使是在HIV疾病症状出现之前，已知会影响免疫功能的微量营养缺乏就